why choose us

First received: March 22, 2023

Clinical Trial: Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Plaque Psoriasis

Study Type: INTERVENTIONAL


Official Title: Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.

Brief Summary: Psoriasis is one of the most common immune-mediated inflammatory disorders characterized by a chronic course.It affects approximately 2-3% of the world's population Psoriasis may be provoked by environmental factors in patients with genetic predispositions.Psoriasis is phenotypically characterized by thickened, red, scaly plaques and systemic inflammation, it is also associated with multiple comorbidities, such as cardiovascular disease, stroke, hypertension, metabolic diseases, chronic kidney disease, and…

Read more